

# Francesco M Marincola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/680910/publications.pdf>

Version: 2024-02-01

140  
papers

13,907  
citations

50276

46  
h-index

24258

110  
g-index

159  
all docs

159  
docs citations

159  
times ranked

22439  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 539.	3.7	8
2	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. <i>British Journal of Cancer</i> , 2021, 124, 760-769.	6.4	13
3	Germline genetic contribution to the immune landscape of cancer. <i>Immunity</i> , 2021, 54, 367-386.e8.	14.3	95
4	Network-based identification of key master regulators associated with an immune-silent cancer phenotype. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	11
5	Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus. <i>American Journal of Pathology</i> , 2021, 191, 1774-1786.	3.8	7
6	Hypoxia and the phenomenon of immune exclusion. <i>Journal of Translational Medicine</i> , 2021, 19, 9.	4.4	63
7	Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers. <i>Journal of Translational Medicine</i> , 2021, 19, 459.	4.4	11
8	Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy. , 2020, 8, e001619.		14
9	Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKε complex inhibitor BX795. <i>Journal of Translational Medicine</i> , 2020, 18, 363.	4.4	12
10	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
11	Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. <i>Journal of Translational Medicine</i> , 2020, 18, 192.	4.4	7
12	Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 604967.	4.8	12
13	Status of Immune Oncology: Challenges and Opportunities. <i>Methods in Molecular Biology</i> , 2020, 2055, 3-21.	0.9	6
14	The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. <i>Cancer Treatment and Research</i> , 2020, 180, 173-195.	0.5	48
15	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 2792-2813.	2.4	12
16	Functional Genome Profiling to Understand Cancer Immune Responsiveness. <i>Methods in Molecular Biology</i> , 2020, 2055, 231-244.	0.9	0
17	The Biology of Immune-Active Cancers and Their Regulatory Mechanisms. <i>Cancer Treatment and Research</i> , 2020, 180, 149-172.	0.5	5
18	Sugar alcohol provides imaging contrast in cancer detection. <i>Scientific Reports</i> , 2019, 9, 11092.	3.3	7

#	ARTICLE	IF	CITATIONS
19	First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. <i>Journal of Translational Medicine</i> , 2019, 17, 271.	4.4	23
20	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. <i>Scientific Reports</i> , 2019, 9, 8572.	3.3	36
21	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
22	Monoallelic expression in melanoma. <i>Journal of Translational Medicine</i> , 2019, 17, 112.	4.4	2
23	Evolution of Metastases in Space and Time under Immune Selection. <i>Cell</i> , 2018, 175, 751-765.e16.	28.9	322
24	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	6.4	54
25	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
26	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
27	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	13.7	1,487
28	Altered structural brain changes and neurocognitive performance in pediatric HIV. <i>NeuroImage: Clinical</i> , 2017, 14, 316-322.	2.7	38
29	NOS1 S-nitrosylates PTEN and inhibits autophagy in nasopharyngeal carcinoma cells. <i>Cell Death Discovery</i> , 2017, 3, 17011.	4.7	29
30	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	4.6	146
31	Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	7.0	149
32	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017, 81, 116-129.	2.8	443
33	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. <i>Oncolmmunology</i> , 2017, 6, e1323618.	4.6	42
34	Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling. <i>Cell Death and Disease</i> , 2017, 8, e2844-e2844.	6.3	23
35	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
36	Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. <i>Journal of Virology</i> , 2017, 91, .	3.4	39

#	ARTICLE	IF	CITATIONS
37	Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. <i>Nature Communications</i> , 2017, 8, 1109.	12.8	111
38	Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection. <i>Journal of Translational Medicine</i> , 2017, 15, 119.	4.4	13
39	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2229.	4.1	105
40	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
41	Cancer immune resistance: can theories converge?. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 411-419.	2.6	13
42	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
43	Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. <i>Oncotarget</i> , 2016, 7, 30193-30210.	1.8	116
44	Evaluation of cognitivity, proinflammatory cytokines, and brain magnetic resonance imaging in minimal hepatic encephalopathy induced by cirrhosis and extrahepatic portal vein obstruction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1986-1994.	2.8	11
45	Interferon- $\beta$ and Tumor Necrosis Factor- $\alpha$ Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. <i>Scientific Reports</i> , 2016, 6, 26345.	3.3	69
46	Differential Responsiveness to Braf Inhibitors of Melanoma Cell Lines Braf V600e-Mutated. , 2016, , .		0
47	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
48	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. <i>Oncotarget</i> , 2016, 5, e1240857.	4.6	56
49	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	3.0	8
50	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. <i>Cancer Immunology Research</i> , 2016, 4, 600-610.	3.4	86
51	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. <i>Cellular and Molecular Immunology</i> , 2016, 13, 502-513.	10.5	99
52	IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. <i>Cancer Immunology Research</i> , 2016, 4, 983-994.	3.4	34
53	Gender-based analysis of cortical thickness and structural connectivity in Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 2308-2318.	3.6	32
54	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1189-1199.	4.2	38

#	ARTICLE	IF	CITATIONS
55	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1201-1212.	4.2	36
56	Lactate Chemical Exchange Saturation Transfer (LATEST) Imaging in vivo: A Biomarker for LDH Activity. <i>Scientific Reports</i> , 2016, 6, 19517.	3.3	62
57	Two hits in one: whole genome sequencing unveils LIG4 syndrome and urofacial syndrome in a case report of a child with complex phenotype. <i>BMC Medical Genetics</i> , 2016, 17, 84.	2.1	17
58	Characterization of viscosupplementation formulations using chemical exchange saturation transfer (ViscoCEST). <i>Journal of Translational Medicine</i> , 2016, 14, 92.	4.4	10
59	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	1.4	45
60	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. <i>Cell Metabolism</i> , 2016, 23, 63-76.	16.2	291
61	Single versus combination immunotherapy drug treatment in melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 433-441.	3.1	16
62	Editorial overview: Tumour immunology: What's beyond today's success in tumor immunology. <i>Current Opinion in Immunology</i> , 2016, 39, viii-x.	5.5	2
63	Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 26866-26878.	1.8	40
64	Vasoactive Intestinal Peptide Protects Cancer Stem Cells from Apoptosis by Activating Multiple Signaling Pathways. , 2016, , .		0
65	Defining genetic modulators of intratumoral immune response in breast cancer through a system biology approach. , 2016, , .		0
66	Monoallelic Expression in Melanoma. , 2016, , .		0
67	Altered Gray Matter Volume and Structural Connectivity in Pediatric Cirrhotic. , 2016, , .		0
68	“Emergency exit” of bone-marrow-resident CD34 <sup>+</sup> DNAM-1 <sup>bright</sup> CXCR4 <sup>+</sup> -committed lymphoid precursors during chronic infection and inflammation. <i>Nature Communications</i> , 2015, 6, 8109.	12.8	22
69	What’s new in melanoma? Combination!. <i>Journal of Translational Medicine</i> , 2015, 13, 213.	4.4	38
70	Molecular magnetic resonance imaging in cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 313.	4.4	79
71	Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. <i>Journal of Translational Medicine</i> , 2015, 13, 306.	4.4	18
72	Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology. <i>Journal of Translational Medicine</i> , 2015, 13, 322.	4.4	2

#	ARTICLE	IF	CITATIONS
73	Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	4.6	119
74	Prognostic and predictive immune gene signatures in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 433-444.	2.4	75
75	Ran signaling in melanoma: Implications for the development of alternative therapeutic strategies. <i>Cancer Letters</i> , 2015, 357, 286-296.	7.2	11
76	The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015, 9, 93-104.	4.6	28
77	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. <i>Cancer Research</i> , 2015, 75, 296-305.	0.9	283
78	2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. <i>EBioMedicine</i> , 2015, 2, 92-93.	6.1	51
79	Preamble to the 2015 SITC immunotherapy biomarkers taskforce. , 2015, 3, 8.		3
80	Obesity susceptibility loci in Qataris, a highly consanguineous Arabian population. <i>Journal of Translational Medicine</i> , 2015, 13, 119.	4.4	21
81	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28 <sup>+</sup> Costimulated T Cells Prepared for Adoptive Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2840-2850.	7.0	52
82	T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015, 7, 598-604.	2.7	29
83	BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. <i>Oncolmmunology</i> , 2015, 4, e1014246.	4.6	50
84	Cisil actively silences TCR signaling in CD8 <sup>+</sup> T cells to maintain tumor tolerance. <i>Journal of Experimental Medicine</i> , 2015, 212, 2095-2113.	8.5	147
85	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. <i>Cancer Immunology Research</i> , 2015, 3, 37-47.	3.4	24
86	Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. <i>Journal of Clinical Investigation</i> , 2015, 126, 318-334.	8.2	193
87	Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. <i>Oncotarget</i> , 2015, 6, 11395-11406.	1.8	23
88	Evidence for CD19 <sup>+</sup> (B) CD8 <sup>+</sup> (T)-Cell Interactions in Blood and Tissues from Patients with Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 4287-4287.	1.4	0
89	Cancer Diagnostic and Predictive Biomarkers. <i>BioMed Research International</i> , 2014, 2014, 1-3.	1.9	12
90	Meta-analysis and metagenes. <i>Oncolmmunology</i> , 2014, 3, e28727.	4.6	12

#	ARTICLE	IF	CITATIONS
91	Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer. Journal of Translational Medicine, 2014, 12, 304.	4.4	51
92	Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology. Journal of Investigative Dermatology, 2014, 134, 1389-1396.	0.7	3
93	Expression of concern: Clinical use of dielectrophoresis separation for live adipose derived stem cells. Journal of Translational Medicine, 2014, 12, 297.	4.4	2
94	Expression of concern: Autologous fat transfer with in-situ mediation (AIM): a novel and compliant method of adult mesenchymal stem cell therapy. Journal of Translational Medicine, 2014, 12, 298.	4.4	0
95	Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. , 2014, 2, 1.		35
96	Modulation of mRNA circadian transcription cycle by microRNAs. , 2014, , .		0
97	Differential Responses of Plasmacytoid Dendritic Cells to Influenza Virus and Distinct Viral Pathogens. Journal of Virology, 2014, 88, 10758-10766.	3.4	28
98	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395.	8.2	106
99	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. Molecular Therapy - Oncolytics, 2014, 1, 14009.	4.4	2
100	The Immune-related Role Of Braf In Melanoma. , 2014, , .		0
101	Effects Of Rituximab On The Response To Influenza Vaccine In Complete Remission Lymphoma Patients. , 2014, , .		0
102	Discrimination between Von Hippel-Lindau gene and hypoxia-regulated alterations in the metabolism and protein expression in renal cell carcinoma using ome-based strategies.. Journal of Clinical Oncology, 2014, 32, 447-447.	1.6	0
103	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. , 2013, 1, 11.		56
104	Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment. Science, 2013, 342, 967-970.	12.6	1,715
105	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity, 2013, 39, 11-26.	14.3	700
106	Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. Journal of Clinical Oncology, 2013, 31, 2369-2371.	1.6	56
107	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine, 2013, 11, 145.	4.4	82
108	The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics, 2012, 13, 156.	2.8	29

#	ARTICLE	IF	CITATIONS
109	IRF5 gene polymorphisms in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 170.	4.4	36
110	Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. <i>International Journal of Cancer</i> , 2012, 131, 387-395.	5.1	75
111	A signature of immune function genes associated with recurrence-free survival in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 871-880.	2.5	166
112	A human memory T cell subset with stem cell-like properties. <i>Nature Medicine</i> , 2011, 17, 1290-1297.	30.7	1,547
113	The trouble with translational medicine. <i>Journal of Internal Medicine</i> , 2011, 270, 123-127.	6.0	54
114	Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. <i>Journal of Translational Medicine</i> , 2011, 9, 174.	4.4	85
115	Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7440-7450.	7.0	74
116	Gene-expression profiling in vaccine therapy and immunotherapy for cancer. <i>Expert Review of Vaccines</i> , 2010, 9, 555-565.	4.4	63
117	Future of immunotherapy: a call for comparative immunology. <i>Immunotherapy</i> , 2009, 1, 1-3.	2.0	4
118	A HCMV pp65 polypeptide promotes the expansion of CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells across a wide range of HLA specificities. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2131-2147.	3.6	10
119	Global Transcriptional Analysis for Biomarker Discovery and Validation in Cellular Therapies. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 181-193.	3.8	8
120	The immunologic constant of rejection. <i>Trends in Immunology</i> , 2008, 29, 256-262.	6.8	145
121	Tumour immunity: effector response to tumour and role of the microenvironment. <i>Lancet</i> , The, 2008, 371, 771-783.	13.7	476
122	Fetal-to-Adult Hemoglobin Switching Is Associated with up-Regulation of Specific MicroRNA Species in Circulating Human Erythroid Cells. <i>Blood</i> , 2008, 112, 1865-1865.	1.4	1
123	The Emerging Role of RH Genotyping in Chronically Transfused Sickle Cell Disease Patients. <i>Blood</i> , 2008, 112, 3035-3035.	1.4	0
124	Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. <i>Genome Biology</i> , 2007, 8, R8.	9.6	100
125	A balanced review of the status T cell-based therapy against cancer. <i>Journal of Translational Medicine</i> , 2005, 3, 16.	4.4	23
126	Immune Monitoring of Cancer Vaccines. <i>Yonsei Medical Journal</i> , 2004, 45, S71A2.	2.2	0



#	ARTICLE	IF	CITATIONS
127	Translational Medicine: A two-way road. <i>Journal of Translational Medicine</i> , 2003, 1, 1.	4.4	227
128	Introduction of article-processing charges (APCs) for articles accepted for publication in the <i>Journal of Translational Medicine</i> . <i>Journal of Translational Medicine</i> , 2003, 1, 11.	4.4	6
129	Tumors as elusive targets of T-cell-based active immunotherapy. <i>Trends in Immunology</i> , 2003, 24, 334-341.	6.8	187
130	Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. <i>Genome Biology</i> , 2002, 3, research0035.1.	9.6	151
131	Tumor Microenvironment: What have we Learned Studying the Immune Response in this Puzzling Battlefield?. <i>Tumori</i> , 2002, 88, 437-444.	1.1	4
132	Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. <i>Cancer Research</i> , 2002, 62, 3581-6.	0.9	208
133	Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. <i>International Journal of Cancer</i> , 2001, 93, 236-242.	5.1	54
134	The impact of genomics on the biotechnology industry. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 749-751.	3.1	0
135	Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. <i>Journal of Cellular Physiology</i> , 2000, 182, 332-338.	4.1	30
136	High-fidelity mRNA amplification for gene profiling. <i>Nature Biotechnology</i> , 2000, 18, 457-459.	17.5	650
137	Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an <i>in vitro</i> melanoma model. <i>International Journal of Cancer</i> , 1999, 80, 781-790.	5.1	73
138	Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an <i>in vitro</i> melanoma model. , 1999, 80, 781.		1
139	Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma <i>in vivo</i> . , 1998, 75, 517-524.		160
140	Immune Responsiveness of Human Tumours. , 0, , 133-151.		1